Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2020-11-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Test the safety of the research study drug, lenalidomide, when given with Idarubicin and
Cytarabine
- See how many respond to combination treatment with lenalidomide, Idarubicin and
Cytarabine
- See how long people respond to this combination therapy
- See how long people live after being treated with this combination of drugs
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute